All In Biotech

Drug Trial Radar · NCT03333928

A POC and Dose-Ranging Study of HTD1801 in PSC Patients

A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)

Last checked: Nov 19, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

59

Actual

Start

Feb 9, 2018

Primary completion

Apr 30, 2020

Study completion Aug 14, 2020

Sponsor

Sponsor type
Industry
First posted
Nov 7, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study was a dose-ranging, 18-week study comparing two doses of HTD1801 (500 mg BID and 1000 mg BID) to placebo in adult subjects with PSC.

Conditions

  • Primary Sclerosing Cholangitis (PSC)

Interventions

  • HTD1801Drug

    HTD1801 tablets, 250 mg

  • PlaceboDrug

    tablets manufactured to mimic HTD1801 tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change in Serum Alkaline Phosphatase (ALP) From Baseline to Week 6 in Period 1Time frame: Baseline to Week 6

Locations

26 sites in 2 countries. Site status is shown where the registry gives one.

  • Arizona Liver Health

    Chandler, Arizona

  • Arizona Liver Health

    Tuscon, Arizona

  • Fresno Clinical Research Center

    Fresno, California

  • Keck School of Medicine of USC

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • University of Colorado, Denver

    Aurora, Colorado

  • South Denver Gastroenterology, PC

    Englewood, Colorado

  • Yale School of Medicine

    New Haven, Connecticut

  • Florida Research Institute

    Lakewood Rch, Florida

  • University of Miami

    Miami, Florida

  • Mercy Medical Center

    Baltimore, Maryland

  • Walter Reed National Military Medical Center

    Bethesda, Maryland

  • Michigan Medicine University of Michigan

    Ann Arbor, Michigan

  • Gastrointestinal Associates

    Flowood, Mississippi

  • Washington University School of Medicine

    St Louis, Missouri

  • Mount Sinai - Icahn School of Medicine

    New York, New York

  • Cumberland Research Associates

    Fayetteville, North Carolina

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina

  • Gastro One

    Germantown, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Pinnacle Clinical Research

    Austin, Texas

  • Pinnacle Clinical Research

    San Antonio, Texas

  • Swedish Medical Center

    Seattle, Washington

  • University of Washington

    Seattle, Washington

  • Aspen Woods Clinic

    Calgary, Alberta, Canada

  • Toronto Centre for Liver Disease, Toronto General Hospital

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.